Tags

Type your tag names separated by a space and hit enter

Peripherally Restricted Cannabinoids for the Treatment of Pain.

Abstract

The use of cannabinoids for the treatment of chronic diseases has increased in the United States, with 23 states having legalized the use of marijuana. Although currently available cannabinoid compounds have shown effectiveness in relieving symptoms associated with numerous diseases, the use of cannabis or cannabinoids is still controversial mostly due to their psychotropic effects (e.g., euphoria, laughter) or central nervous system (CNS)-related undesired effects (e.g., tolerance, dependence). A potential strategy to use cannabinoids for medical conditions without inducing psychotropic or CNS-related undesired effects is to avoid their actions in the CNS. This approach could be beneficial for conditions with prominent peripheral pathophysiologic mechanisms (e.g., painful diabetic neuropathy, chemotherapy-induced neuropathy). In this article, we discuss the scientific evidence to target the peripheral cannabinoid system as an alternative to cannabis use for medical purposes, and we review the available literature to determine the pros and cons of potential strategies that can be used to this end.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pharmaceutical and Administrative Sciences, Presbyterian College School of Pharmacy, Clinton, South Carolina.

    ,

    Department of Pharmaceutical and Administrative Sciences, Presbyterian College School of Pharmacy, Clinton, South Carolina.

    ,

    Department of Pharmaceutical and Administrative Sciences, Presbyterian College School of Pharmacy, Clinton, South Carolina.

    Department of Pharmaceutical and Administrative Sciences, Presbyterian College School of Pharmacy, Clinton, South Carolina.

    Source

    Pharmacotherapy 35:10 2015 Oct pg 917-25

    MeSH

    Administration, Cutaneous
    Analgesics
    Blood-Brain Barrier
    Cannabinoids
    Chronic Disease
    Diabetic Neuropathies
    Humans
    Medical Marijuana
    Neuralgia, Postherpetic
    Pain
    Peripheral Nervous System Diseases
    Receptors, Cannabinoid
    United States

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    26497478

    Citation

    Romero-Sandoval, E Alfonso, et al. "Peripherally Restricted Cannabinoids for the Treatment of Pain." Pharmacotherapy, vol. 35, no. 10, 2015, pp. 917-25.
    Romero-Sandoval EA, Asbill S, Paige CA, et al. Peripherally Restricted Cannabinoids for the Treatment of Pain. Pharmacotherapy. 2015;35(10):917-25.
    Romero-Sandoval, E. A., Asbill, S., Paige, C. A., & Byrd-Glover, K. (2015). Peripherally Restricted Cannabinoids for the Treatment of Pain. Pharmacotherapy, 35(10), pp. 917-25. doi:10.1002/phar.1642.
    Romero-Sandoval EA, et al. Peripherally Restricted Cannabinoids for the Treatment of Pain. Pharmacotherapy. 2015;35(10):917-25. PubMed PMID: 26497478.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Peripherally Restricted Cannabinoids for the Treatment of Pain. AU - Romero-Sandoval,E Alfonso, AU - Asbill,Scott, AU - Paige,Candler A, AU - Byrd-Glover,Kiara, PY - 2015/10/27/entrez PY - 2015/10/27/pubmed PY - 2016/8/16/medline KW - cannabinoids KW - chronic pain KW - inflammatory pain KW - marijuana KW - neuropathic pain KW - psychotropic effects SP - 917 EP - 25 JF - Pharmacotherapy JO - Pharmacotherapy VL - 35 IS - 10 N2 - The use of cannabinoids for the treatment of chronic diseases has increased in the United States, with 23 states having legalized the use of marijuana. Although currently available cannabinoid compounds have shown effectiveness in relieving symptoms associated with numerous diseases, the use of cannabis or cannabinoids is still controversial mostly due to their psychotropic effects (e.g., euphoria, laughter) or central nervous system (CNS)-related undesired effects (e.g., tolerance, dependence). A potential strategy to use cannabinoids for medical conditions without inducing psychotropic or CNS-related undesired effects is to avoid their actions in the CNS. This approach could be beneficial for conditions with prominent peripheral pathophysiologic mechanisms (e.g., painful diabetic neuropathy, chemotherapy-induced neuropathy). In this article, we discuss the scientific evidence to target the peripheral cannabinoid system as an alternative to cannabis use for medical purposes, and we review the available literature to determine the pros and cons of potential strategies that can be used to this end. SN - 1875-9114 UR - https://www.unboundmedicine.com/medline/citation/26497478/Peripherally_Restricted_Cannabinoids_for_the_Treatment_of_Pain_ L2 - https://doi.org/10.1002/phar.1642 DB - PRIME DP - Unbound Medicine ER -